Related Experiment Video

Updated: Aug 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

A rationale for the use of anticoagulation in heart failure management

Todd Pulerwitz1, LeRoy E Rabbani, Sean P Pinney

  • 1Division of Cardiology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

Journal of Thrombosis and Thrombolysis
|August 13, 2004
PubMed

Insights

Anticoagulation benefits in heart failure are unclear, lacking specific guidelines for cardiac dysfunction. This review explores thrombus formation, current recommendations, and ongoing trials to clarify its use.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Public Health

Background:

  • Heart failure (HF) is a significant public health issue with evolving treatments.
  • Established therapies like beta-blockers and ACE inhibitors improve HF outcomes.
  • The role of anticoagulation in HF, particularly with isolated cardiac dysfunction, remains uncertain.

Purpose of the Study:

  • To summarize the pathophysiology of thrombus formation in heart failure.
  • To review existing studies and guidelines on anticoagulation in HF.
  • To provide a rationale for anticoagulation in the absence of definitive data and discuss ongoing trials.

Main Methods:

  • Literature review of studies on anticoagulation in heart failure.
  • Analysis of current clinical guidelines for atrial fibrillation and stroke.
  • Examination of epidemiological data on stroke risk in cardiomyopathy.

Main Results:

  • Increased risk of thrombus and stroke in heart failure patients correlates with reduced ejection fraction.
  • Current guidelines lack specific recommendations for anticoagulation in isolated cardiac dysfunction.
  • Clinician discretion is key in balancing stroke reduction benefits against bleeding risks.

Conclusions:

  • The precise indications for anticoagulation in heart failure patients with impaired ejection fraction require further clarification.
  • Ongoing clinical trials aim to provide evidence-based recommendations for anticoagulation in this population.
  • Further research is essential to optimize anticoagulation strategies in heart failure management.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...